Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Racura Oncology Ltd has officially changed its name from Race Oncology Limited following shareholder approval and registration with the Australian Securities and Investments Commission. The company’s ASX listing code remains unchanged. This rebranding aligns with Racura’s mission to enhance its positioning in the biopharmaceutical industry, focusing on innovative cancer treatments and strategic collaborations to expand its market reach.
More about Race Oncology Ltd.
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company focused on cancer care. Its lead asset, RCDS1, is an anticancer agent targeting G4-DNA & RNA binding, inhibiting the MYC cancer growth regulator. Racura is advancing RCDS1 for various oncology indications and is exploring partnerships to accelerate global patient access.
Average Trading Volume: 549,495
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.1M
Learn more about RAC stock on TipRanks’ Stock Analysis page.